Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03891706
• Other study ID #: FI-FIT001-001
• Status: Recruiting
• Phase: Phase 1
• Start date: January 8, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: September 2023
• Source: Guangzhou FineImmune Biotechnology Co., LTD.
• Contact: Xuzhi Pan
• Phone: 86-20-87343135
• Email: panxzh[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .

The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .

Description:

This study is an open, single-center, phase I clinical trial which is aim to evaluate the safety and tolerability of tumor-specific TCR-T cells. In this study, these TCR-T cells will be multiplied, or grown, in the laboratory.Subjects will received TCR-T cells infusions twice at day 0 and day 14, with the use of IL-2 for 5 consecutive days after every cell infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged between 18 and 70 years old, regardless of gender;

2. Diagnosed as solid tumors by histopathology, and the tumor lesions could be detected or evaluated;

3. Be after standard treatment or who lack effective treatment programs;

4. Patients and their families were willing to participate in the clinical trial and signed the informed consent;

5. Physical status: ECOG score 0-1;

6. Expected survival time > 3 months;

7. HIV antibody negative;Hepatitis b surface antigen negative;Hepatitis c antibody negative;The results of blood routine and coagulation were roughly normal, lymphocyte >0.8×10^9/L, hemoglobin >100g/L, and the pregnancy test of female patients with fertility potential was negative.

8. Left ventricular ejection fraction 50% as indicated by cardiac ultrasound;Upper normal level of serum ALT/AST < 2.5 times;Serum creatinine 1.6mg/dl;Total bilirubin 1.5mg/dl, subject's total bilirubin < 3mg/dl except for Gilberts Syndrome;

9. At least 4 weeks after the last systemic treatment, the patient's toxic and side effects must be restored to grade 1 or lower (except for alopecia or vitiligo).If the subject undergoes minor surgery within 3 weeks prior to enrollment, as long as all toxicity is recovered to level 1 or lower, the subject will meet the enrollment requirements.

10. During the whole study period, patients can regularly visit the enrolled research institutions for relevant detection, evaluation and management;

11. The patient is not allowed to use any anti-tumor drugs or treatments for 4 weeks prior to the infusion of TCR-T cells;

12. Patients' tumor lesions can be obtained by surgery or puncture, and tumor infiltrating T cells can be successfully isolated from the obtained tumor tissue;

13. T cells in patients' peripheral blood can effectively proliferate and expand by at least 10 times in the Pre-culture;

14. The benefits of participating in the clinical trial outweigh the risks,which was evaluated by the researchers base on the status or condition of the patients.

Exclusion Criteria:

1. Any form of primary immunodeficiency disease (such as severe combined immunodeficiency disease);

2. Experiencing moderate to severe infection or possible opportunistic infection;

3. Patients with a history of autoimmunity (e.g., SLE, psoriasis, etc.);

4. Acute systemic infection, coagulation dysfunction or other serious cardiopulmonary diseases;

5. Patients who have is suffering a large amount of glucocorticoid or other immunosuppressive agents within 4 weeks;

6. Be allergic to any drug used in this study;

7. Central nervous system metastases patients with clinically unstable or acute meningitis (except these clinically stable after treatment) Clinical stability needs to be met as follows: 4 weeks at least before the trial treatment, 1) no new brain lesion or no expanded of the original lesions confirmed by MRI); 2) no hormone therapy for at least 2 weeks; 3) neurological symptoms have returned to baseline;

8. Pregnant and lactating women, as well as male and female patients who could not cooperate with contraception during the study period.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• tumor-specific TCR-T cells
On day 0 and day 14, 0.5-5x10^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
• Interleukin-2
Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Gaungdong

Sponsors (2)

Lead Sponsor	Collaborator
Guangzhou FineImmune Biotechnology Co., LTD.	Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.03	Keep records the adverse events experienced by subjects in 30 days after the last infusion.	At least 45 days
Secondary	Disease Control Rate(DCR)	DCR is defined as the proportion of patients with tumor size reduction(CR,PR) and stable (SD) assessed by RECIST 1.1 and iRECIST	one year
Secondary	overall survival(OS)	The time from the first injection of Investigational Product until death	two year
Secondary	progression-free survival(PFS)	PFS is defined as the time from the first injection of Investigational Product until objective tumor progression or death, whichever occurs first.Assessed by RECIST 1.1 and iRECIST	two year